Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A post-market, parallel group clinical trial of Xeomin (incobotulinumtoxinA) versus Botox Cosmetic (onabotulinumtoxinA) in the treatment of moderate to severe glabellar facial lines.

Next Previous
X
Search
Trial Profile

A post-market, parallel group clinical trial of Xeomin (incobotulinumtoxinA) versus Botox Cosmetic (onabotulinumtoxinA) in the treatment of moderate to severe glabellar facial lines.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Glabellar lines
  • Focus Therapeutic Use

    • Most Recent Events

    • 08 Mar 2016 Results presented at the 74th Annual Meeting of the American Academy of Dermatology
    • 02 Nov 2015 Results published in the journal Dermatologic Surgery, according to a Merz Aestherics media release.
    • 23 Mar 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top